Oxford University and Evotec’s drug discovery partnership launched last year to quickly accelerate drugs to market begins making awards, backing projects targeting cardiovascular and infectious diseases.
Launched last year as a partnership between the University, Evotec and Oxford Sciences Innovation, LAB282 aids the rapid translation of research outputs into new drug discovery and development programmes. It draws on expertise provided by Evotec and combines that with pre-clinical proof-of-concept grant funding to accelerate projects into a position where they can be commercialised and scaled up efficiently and effectively.
Two research projects were chosen out of a wide range of proposals. Further details are provided in the full release here.
Click here to see the Evotec announcement.